House panel mulls ways to boost struggling US biosimilar market
The state of the US biosimilar market isn’t as healthy as it should be despite significant advances in the past decade, health policy experts told …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
